Notification of trade

03 Mar 2025 10:26 CET

Moss, 3 March 2025

Gentian Diagnostics ASA ("Gentian") has today been notified that the following
transactions have been completed:
INSR AS and Norda ASA have each today purchased 614 251 shares in Gentian at NOK
46.50 per share. Following the transactions Insr ASA and Norda ASA own 614,251
shares each in Gentian Diagnostics ASA. Insr ASA and Norda ASA each own about
3.98% of the total outstanding shares following the transactions. Insr ASA and
Norda ASA will together with the Group of companies Kvantia AS, Obligasjon 2 AS,
Caaby AS, RWD AS and Victoria India Fund AS following the share transactions
hold in total 3,422,370 shares in Gentian Diagnostics ASA, corresponding to
approx. 22.2% of the total outstanding shares.

Fredrik Thoresen is a board member and primary insider in Gentian. Please note
that Fredrik Thoresen has no formal role in INSR ASA and Norda ASA. However, it
could be claimed that Fredrik Thoresen has an impact on the investment decisions
in INSR ASA and Norda ASA, therefore we send this notice in order to be
transparent.

PCA notification pursuant to the EU Market Abuse Regulation Article 19 is
attached.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article
19 and Euronext Oslo Rule Book II.

For further information, please contact: Njaal Kind, Group CFO,
njaal.kind@gentian.no, +47 91 90 65 25

More information:
Access the news on Oslo Bors NewsWeb site

640236_Krt skjema Gent kjøp mars 2025.pdf
640236_krt1500 Gentian kjøp Norda mar 2025.pdf